AUBURN, Ala. & SHANGHAI–(BUSINESS WIRE)–Vitruvias Therapeutics Inc., an Auburn, Alabama-based finished-dose generic drug company, and Sinotherapeutics Inc., a Shanghai-based generic drug company, announced they have launched a bioequivalent FDA-approved version of Rythmol SR. Rythmol SR, known generically as propafenone hydrochloride, is an antiarrhythmic drug supplied in extended-release capsules of 225, […]
Other News
Ablative Solutions Announces Results from Treatment of Patients with Hypertension in the European Peregrine Post-Market Study
KALAMAZOO, Mich. & WASHINGTON–(BUSINESS WIRE)–Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced new data from the Peregrine Post-Market Clinical Trial, which were presented this week during a late-breaking session at the 2019 Cardiovascular Research Technologies (CRT) meeting in Washington, D.C. The Peregrine Post-Market […]
PLx Pharma Inc. Reports Fourth Quarter 2018 Results
HOUSTON, March 08, 2019 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together […]
Audio: Hakon Bergheim, COO of Adagio Medical speaks with CardiacVascularNews
Audio recording: Hakon Bergheim, COO of Adagio Medical speaks with CardiacVascularNews
BTG Crossing Devices are Highlighted at the CTO Summit in NY
BOTHELL, WA, March 7, 2019 /PRNewswire/ — BTG plc (LSE: BTG), the global healthcare company, exhibited the BTG Crossing Devices portfolio at the Chronic Total Occlusion (CTO) Summit in New York City from February 28 to March 1. Dr. Alexandre Avran of the Arnault Tzanck Institute in Nice, France, headlined the BTG exhibition at the summit this year, discussing his experience […]
New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations
THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1 as well as a sub-analysis from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER). Additional abstracts […]
Northwestern Medicine and Eko Partner to Improve Valvular Heart Disease Screening Using Machine Learning Algorithms
CHICAGO, March 7, 2019 /PRNewswire/ — Northwestern Medicine Bluhm Cardiovascular Institute is pioneering the use of artificial intelligence (AI) for cardiac screening in a new study of Eko’s cardiac monitoring platform. The study aims to demonstrate that Eko’s digital stethoscopes and AI algorithms can interpret heart sounds accurately to help screen for pathologic heart murmurs and […]
Micro Interventional Devices, Inc.™ Enters Strategic Alliance with OSCOR, Inc.; Closes Series D Financing
NEWTOWN, Pa., March 7, 2019 /PRNewswire/ — Micro Interventional Devices, Inc. (MID) Chairman, President and CEO, Michael Whitman, and OSCOR, Inc. President and CEO, Thomas Osypka, are pleased to announce a strategic alliance that leverages each company’s unique strengths and capabilities to further develop and commercialize innovative solutions to structural heart disease, specifically, MID’s MIA™, Minimally […]
Fist Assist Devices, LLC Announces Formation of Global Medical Advisory Board Led by Dialysis Access Center Medical Director Dr. John Ross
LOS ALTOS, Calif.–(BUSINESS WIRE)–Fist Assist Devices, LLC, a novel medical device start-up based in Silicon Valley, Calif., today announced the formation of its first global medical advisory board (MAB). Fist Assist Devices, LLC has developed the only wearable patent-protected intermittent compression device for vein dilation for patients with end-stage renal […]
Late-Breaking Data Presentations at ACC 2019 Highlight Abbott’s Leading Cardiovascular Portfolio
ABBOTT PARK, Ill., March 6, 2019 /PRNewswire/ — Key medical devices across Abbott’s (NYSE: ABT) cardiovascular portfolio will be highlighted in five late-breaking clinical trials at the American College of Cardiology’s 68th Annual Scientific Session (ACC 2019) from March 16 – 18 in New Orleans. The late-breaking studies showcase the depth and breadth of the company’s cardiovascular portfolio, providing new data […]



